Table 4 Adverse events while taking sirolimus according to the duration of treatment in patients with LAM
From: Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis
Time after sirolimus (years) | Number (%) | |||
|---|---|---|---|---|
Year 1 (N = 107) | Year 2 (N = 70) | Year 3 (N = 53) | Year 4 (N = 30) | |
Mouth ulcer | 73 (68.2) | 33 (47.1) | 22 (41.5) | 7 (23.3) |
Menstrual abnormality | 62 (57.9) | 34 (48.6) | 16 (30.2) | 8 (26.7) |
Acne | 37 (34.6) | 22 (31.4) | 12 (22.6) | 3 (10.0) |
Ovarian cystsa | 17/55 (30.9) | 10/37 (27.0) | 6/25 (24.0) | 1/8 (12.5) |
Weakness | 11 (10) | 1 (1.4) | 0 | 0 |
Peripheral edema | 6 (5.6) | 2 (2.9) | 1 (1.9) | 1 (3.3) |
Diarrhea | 6 (5.6) | 1 (1.4) | 0 | 0 |
Rash | 5 (4.7) | 0 | 0 | 1 (3.3) |
Nausea | 5 (4.7) | 0 | 1 (1.9) | 0 |
Weight loss | 5 (4.7) | 0 | 0 | 0 |
Arthralgia | 4 (3.7) | 0 | 0 | 1 (3.3) |
Abdominal pain | 3 (2.8) | 2 (2.9) | 0 | 0 |
Pruritus | 3 (2.8) | 1 (1.4) | 0 | 0 |
Abdominal distention | 2 (1.9) | 0 | 0 | 0 |
Fever | 2 (1.9) | 0 | 0 | 0 |
Chest pain | 2 (1.9) | 1 (1.4) | 1 (1.9) | 1 (3.3) |
Toothache | 1 (0.9) | 0 | 0 | 0 |
Gingival hyperplasia | 1 (0.9) | 0 | 0 | 0 |
Periodontitis | 1 (0.9) | 0 | 0 | 0 |
Herpes zoster | 1 (0.9) | 1 (1.4) | 0 | 0 |
Alopecia | 1 (0.9) | 0 | 0 | 0 |
Headache | 1 (0.9) | 0 | 0 | 0 |
Dizziness | 1 (0.9) | 0 | 0 | 0 |
Palpitation | 1 (0.9) | 0 | 0 | 0 |
Myalgia | 1 (0.9) | 0 | 0 | 0 |
Tenosynovitis | 1 (0.9) | 0 | 0 | 0 |